Evidence map›Paper›PMID 26932476›Full record

ArticleRNA (New York, N.Y.)2016

Nudt3 is an mRNA decapping enzyme that modulates cell migration.

Ewa Grudzien-Nogalska, Xinfu Jiao, Man-Gen Song, Ronald P Hart, Megerditch Kiledjian

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Role ofZoological research · 2026
    Article
  4. CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion.Virchows Archiv : an international journal of pathology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Application of Mammalian Nudix Enzymes to Capped RNA Analysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  10. Uterine leiomyoma with RAD51B::NUDT3 fusion: a report of 2 cases.Virchows Archiv : an international journal of pathology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. RSC chemical biology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Processing body (P-body) and its mediators in cancer.Molecular and cellular biochemistry · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ewa Grudzien-NogalskaDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, USA.
Xinfu JiaoDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, USA.
Man-Gen SongDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, USA.
Ronald P HartDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, USA.
Megerditch KiledjianDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, USA kiledjian@biology.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

Regulation of Mammalian mRNA DecayR01GM067005 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI KILEDJIAN, MEGERDITCH · 2004 to 2022
$5.5M
NIGMS NIH HHS GM067005NIGMS NIH HHS R01 GM067005
6 · The paper itself

Abstract

Removal of the 5'-end 7-methylguanosine cap structure is a critical step in the highly regulated process of mRNA decay. The Nudix hydrolase, Dcp2, was identified as a first decapping enzyme and subsequently shown to preferentially modulate stability of only a subset of mRNAs. This observation led to the hypothesis that mammalian cells possess multiple decapping enzymes that may function in distinct pathways. Here we report Nudt3 is a Nudix protein that possesses mRNA decapping activity in cells and is a modulator of MCF-7 breast cancer cell migration. Reduction of Nudt3 protein levels in MCF-7 cells promotes increased cell migration and corresponding enhanced filopodia extensions. Importantly, this phenotype was reversed by complementation with wild type, but not catalytically inactive Nudt3 protein indicating Nudt3 decapping activity normally functions to control cell migration. Genome-wide analysis of Nudt3 compromised cells identified elevated levels of transcripts involved in cell motility including integrin β6, lipocalin-2, and fibronectin. The observed increase in mRNA abundance was dependent on Nudt3 decapping activity where integrin β6 and lipocalin-2 were modulated directly through mRNA stability, while fibronectin was indirectly controlled. Moreover, increased cell migration observed in Nudt3 knockdown cells was mediated through the extracellular integrin β6 and fibronectin protein nexus. We conclude that Nudt3 is an mRNA decapping enzyme that orchestrates expression of a subset of mRNAs to modulate cell migration and further substantiates the existence of multiple decapping enzymes functioning in distinct cellular pathways in mammals.

Indexed as

Acid Anhydride HydrolasesCell MovementDown-RegulationEndoribonucleasesFibronectinsGene Knockdown TechniquesHumansIntegrin beta ChainsMCF-7 CellsAcid Anhydride Hydrolasesdiphosphoinositol polyphosphate phosphohydrolaseEndoribonucleasesFibronectinsintegrin beta6Integrin beta ChainsmRNA decapping enzymescell motilityfibronectinintegrin β6mRNA decappingmRNA stabilityNudt3

Identifiers

PMID26932476
PMCPMC4836651
OpenAlexW2289016582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.